Patients with MPO-associated MN showed a significantly higher urinary protein level after 12 months (1.3 [0.5–1.5] vs. 0.2 [0.1–0.4] g/gCr; P = 0.035), a higher rate of fibrous crescents (15.4 [12.2–21.4] vs. 0.0 [0.0–1.8]%; P = 0.012), and a lower MPO-ANCA titer (25.6 [20.6–72.4] vs. 154.0 [91.1–307.5] U/ml; P = 0.035) than those with MPO-ANCA GN. This evidence concerns the gene MPO and ganglioneuroma.